1. Chong, HY, Teoh, SL, Wu, DB-C, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Disease Treat. 2016; 12: 357–373.
2. Emsley, R, Chiliza, B, Asmal, L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013; 13(1): 50.
3. Hosák, L, Hosakova, J. The complex etiology of schizophrenia—general state of the art. Neuro Endocrinol Lett. 2015; 36(7): 631–637.
4. Karlsgodt, KH, Sun, D, Cannon, TD. Structural and functional brain abnormalities in schizophrenia. Curr Dir Psychol Sci. 2010; 19(4): 226–231.
5. Baldessarini, RJ, Tarazi, FI. Pharmacotherapy of Psychosis and Mania. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2005; 11: 461–500.
6. Lewis, DA, Sweet, RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009; 119(4): 706–716.
7. Lieberman, J, Stroup, T, McEvoy, J, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.
8. Davidson, M, Galderisi, S, Weiser, M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009; 166(6): 675–682.
9. Haddad, PM, Brain, C, Scott, J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014; 5: 43–62.
10. Jones, KA, Menniti, FS, Sivarao, DV. Translational psychiatry—light at the end of the tunnel. Ann N Y Acad Sci. 2015; 1344(1): 1–11.
11. Atkinson, AJ, Colburn, WA, DeGruttola, VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 89–95.
12. Weickert, CS, Weickert, TW, Pillai, A, et al. Biomarkers in schizophrenia: a brief conceptual consideration. Disease Markers. 2013; 35(1): 3–9.
13. Pickard, BS. Schizophrenia biomarkers: translating the descriptive into the diagnostic. J Psychopharmacol. 2015; 29(2): 138–143.
14. Sethi, S, Brietzke, E. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2016; 19(3): pyv096.
15. Holmes, E, Wilson, ID, Nicholson, JK. Metabolic phenotyping in health and disease. Cell. 2008; 134(5): 714–717.
16. Griffiths, WJ, Koal, T, Wang, Y, et al. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010; 49(32): 5426–5445.
17. Orešič, M, Tang, J, Seppänen-Laakso, T, et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011; 3(3): 19.
18. Yang, J, Chen, T, Sun, L, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013; 18(1): 67–78.
19. He, Y, Yu, Z, Giegling, I, et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012; 2(8): e149.
20. Gan, JL, Cheng, ZX, Duan, HF, et al. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: a magnetic resonance spectroscopy study. Psychiatry Res. 2014; 223(1): 23–27.
21. Xuan, J, Pan, G, Qiu, Y, et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011; 10(12): 5433–5443.
22. Tkachev, D, Mimmack, ML, Huffaker, SJ, et al. Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol. 2007; 10(4): 557–563.
23. Holmes, E, Tsang, TM, Huang, JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006; 3(8): e327.
24. Kaddurah-Daouk, R, McEvoy, J, Baillie, R, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007; 12(10): 934–945.
25. Cai, HL, Li, HD, Yan, XZ, et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012; 11(8): 4338–4350.
26. Fukushima, T, Iizuka, H, Yokota, A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014; 9(7): e101652.
27. Guest, PC, Schwarz, E, Krishnamurthy, D, et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011; 36(7): 1092–1096.
28. Palomino, A, González-Pinto, A, Martinez-Cengotita, , et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 44: 29–33.
29. Beckmann, H, Gattaz, W. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. J Neural Transm. 2002; 109(5): 931–938.
30. Linderholm, KR, Skogh, E, Olsson, SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2010; 38(3): 426–432.
31. Ohrmann, P, Kugel, H, Bauer, J, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res. 2008; 106(2): 156–163.
32. Liu, P, Jing, Y, Collie, N, et al. Altered brain arginine metabolism in schizophrenia. Transl Psychiatry. 2016; 6(8): e871.
33. Yao, J, Zhou, X, Keshavan, M. Homeostatic imbalance of adenosine signaling and uric acid production in schizophrenia. Schizophr Bull. 2017; 43(Suppl 1): S89.
34. Chan, MK, Gottschalk, MG, Haenisch, F, et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol. 2014; 122: 45–72.
35. Harris, LW, Guest, PC, Wayland, MT, et al. Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology. 2013; 38(6): 752–766.
36. Harris, LW, Pietsch, S, Cheng, TM, et al. Comparison of peripheral and central schizophrenia biomarker profiles. PloS One. 2012; 7(10): e46368.
37. Plitman, E, Nakajima, S, de la Fuente-Sandoval, C, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol. 2014; 24(10): 1591–1605.
38. Lisman, JE, Coyle, JT, Green, RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008; 31(5): 234–242.
39. Chen, Y, Guillemin, GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009; 2: 1–19.
40. Muller, N, Myint, AM, Schwarz, MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Design. 2011; 17(2): 130–136.
41. Volk, DW, Gonzalez-Burgos, G, Lewis, DA. l-Proline, GABA synthesis and gamma oscillations in schizophrenia. Trends Neurosci. 2016; 39(12): 797–798.
42. Najjar, S, Pearlman, DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015; 161(1): 102–112.
43. Calabrese, V, Giordano, J, Crupi, R. Hormesis, cellular stress response and neuroinflammation in schizophrenia: early onset versus late onset state. J Neurosci Res. 2017; 95(5): 1182–1193.
44. Bou Khalil, R. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses. 2011; 77(3): 427–429.
45. Liu, F, Guo, X, Wu, R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1): 169–176.
46. Ghanizadeh, A, Dehbozorgi, S, OmraniSigaroodi, M, et al. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov. 2014; 8(3): 211–215.
47. Zhang, L, Zhao, J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014; 10: 1103–1111.
48. Shim, S, Shuman, M, Duncan, E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophr Res. 2016; 170(1): 226–231.
49. Breier, A, Hummer, T, Liffick, E, et al. The effects of 12-month, double-blind N-acetyl cysteine treatment on symptoms and brain structures in early phase psychosis. Biol Psychiatry. 2017; 81(10): S164.
50. Harvey, PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009; 19(3): 324–335.
51. Goff, DC, Romero, K, Paul, J, et al. Biomarkers for drug development in early psychosis: current issues and promising directions. Eur Neuropsychopharmacol. 2016; 26(6): 923–937.
52. Kegel, ME, Bhat, M, Skogh, E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014; 7: 15–22.
53. Schwarcz, R, Bruno, JP, Muchowski, PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13(7): 465–477.
54. Wonodi, I, Schwarcz, R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010; 36(2): 211–218.
55. Wonodi, I, Stine, OC, Sathyasaikumar, KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011; 68(7): 665–674.
56. Goff, DC, Lamberti, JS, Leon, AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008; 33(3): 465–472.
57. Goff, DC, Hill, M, Barch, D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99(2): 245–253.
58. Beinat, C, Banister, SD, Herrera, M, et al. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs. 2015; 29(7): 529–542.
59. Javitt, DC, Carter, CS, Krystal, JH, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018; 75(1): 11–19.